| Literature DB >> 34915901 |
Lu Tang1,2, Qiaqia Xiao1,2, Yijun Mei1,2, Shun He1,2, Ziyao Zhang1,2, Ruotong Wang1,2, Wei Wang3,4.
Abstract
Despite the exciting breakthroughs in medical technology, cancer still accounts for one of the principle triggers of death and conventional therapeutic modalities often fail to attain an effective cure. Recently, nanobiotechnology has made huge advancement in cancer therapy with gigantic application potential because of their ability in achieving precise and controlled drug release, elevating drug solubility and reducing adverse effects. Carbon nanotubes (CNTs), one of the most promising carbon-related nanomaterials, have already achieved much success in biomedical field. Due to their excellent optical property, thermal and electronic conductivity, easy functionalization ability and high drug loading capacity, CNTs can be applied in a multifunctional way for cancer treatment and diagnosis. In this review, we will give an overview of the recent progress of CNT-based drug delivery systems in cancer theranostics, which emphasizes their targetability to intracellular components of tumor cells and extracellular elements in tumor microenvironment. Moreover, a detailed introduction on how CNTs penetrate inside the tumor cells to reach their sites of action and achieve the therapeutic effects, as well as their diagnostic applications will be highlighted.Entities:
Keywords: Cancer theranostics; Carbon nanotubes; Intracellular targeting; Targeted drug delivery; Tumor microenvironment
Mesh:
Substances:
Year: 2021 PMID: 34915901 PMCID: PMC8679967 DOI: 10.1186/s12951-021-01174-y
Source DB: PubMed Journal: J Nanobiotechnology ISSN: 1477-3155 Impact factor: 10.435
Fig. 1Schematic overview of the diverse applications of CNTs in cancer theranostics
Fig. 2Schematic demonstration of different functionalization methods of CNTs. CNTs can be functionalized in covalent and non-covalent ways through various chemical groups, ligands and polymers to improve their solubility, biocompatibility and biodegradability for active drug targeting and deep tumor penetration
Summary of the functionalization of CNTs through various molecules
| Type of CNTs | Functionalized molecules | Effectiveness | Tumor model | Biocompatibility test | Refs. |
|---|---|---|---|---|---|
| SWNTs | PEG | Increase solubility, prevent particle aggregation, decrease side effect of the whole DDS | Gastric cancer | Show decreased toxicity towards normal tissue | [ |
| Both SWNTs and MWNTs | PEI | Improve the solubility, homogeneity and dispersity, reduce the particle size, increase the positive charge to interact with siRNA | Cervical cancer | N/A | [ |
| SWNTs | Hyaluronic acid | Enhance the serum stability and target CD44-overexpressing cancer cells, overcome the multidrug resistance | Ovarian cancer | Show no cytotoxicity towards normal tissue with no body weight drop in mice | [ |
| MWNTs | Chitosan | Increase the water solubility and cell-penetrating ability, decrease the toxicity | Breast cancer | Show low cytotoxicity | [ |
| MWNTs | PLGA | Improve the dispersity, reduce toxicity, provide attachment sites for drugs and tune the temporal release | Osteosarcoma | Show low cytotoxicity in normal cells | [ |
| SWNTs | CD33 mAB | Recognize and specifically target the GNM-CD33+ cells | Glioblastoma | N/A | [ |
| SWNTs | IGF1R mAB and HER2 mAB | Enable the multi-component to target IGF1R and HER2 surface receptors | Breast cancer | Exhibit negligible in vitro toxicity in normal cells | [ |
| SWNTs | RGD peptide | Target αvβ3-expressing cancer cells | Malignant melanoma | Induce little toxicity in vitro | [ |
| SWNTs | EGF receptor | Achieve active targeting ability and enhance the uptake of drugs | Head and neck squamous carcinoma | Show negligible toxicity in vitro and in vivo | [ |
Application of CNT-based DDS in targeting various intracellular therapeutic spots and TME components
| Targeting spot | Drug delivery system | Therapeutic modality | Tumor model | Effectiveness | Biocompatibility test | Refs. |
|---|---|---|---|---|---|---|
| Nucleus | PEG-SWNTs-DOX | Photothermal therapy + Chemotherapy | Breast cancer | Increase delivery efficiency, promote the accumulation and localization of DOX inside the nucleus, cause effective cancer cell death | N/A | [ |
| Nucleus | SWNTs-carrier | Chemotherapy | Colorectal cancer | Achieve targeted therapy and controlled drug release | Show good biocompatibility | [ |
| Nucleus | Gene therapy | Breast cancer | Transport the target gene into the nucleus effectively, induce apoptosis strongly | N/A | [ | |
| Cytoplasm | Chim/PEI/5-FU/CNT nanoparticles | Gene therapy + Chemotherapy | Gastric cancer | Achieve targeted delivery and silence the drug-resistant gene, promote the apoptosis of drug-resistant cancer cells | Show negligible in vivo toxicity, and none of the mice dead after treatment with no statistically significant difference in body weight between the groups | [ |
| Cytoplasm | MWNTs/Sor/siRNA | Gene therapy + Chemotherapy | Liver cancer | Enhance the release of sorafenib and improve siRNA stability, display significant antitumor effect | N/A | [ |
| Cytoplasm | SWNT-HIF-1α siRNA complexes | Gene therapy | Pancreas cancer | Transfect and induce the RNAi response, effectively suppress tumor growth | Negligible toxic effect in vitro and in vivo | [ |
| Cytoplasm | oxDWNT-siRNA | Gene therapy | Prostate cancer | Release siRNA into the cytoplasm to suppress survivin protein synthesis, directly cause cancer cell apoptosis | Show good biocompatibility | [ |
| Mitochondria | MWNT-Rho (PtBzt + BP) | Chemotherapy | Ovarian cancer | Increase the selectivity of platinum-based chemotherapy, minimize the side effects | N/A | [ |
| Mitochondria | PEG-CNTs-ABT737 | Chemotherapy | Lung cancer | Improve the mitochondrial targeting of lung cancer cells, cause cancer cell apoptosis | Show lower cytotoxicity in NHFB normal cells than A549 lung cancer cells | [ |
| Mitochondria | P-D-CS-CNTs | Photothermal therapy | Bladder cancer | Enhance mitochondrial targeting, induce the ROS burst, result in mitochondrial damage and cell death | N/A | [ |
| Mitochondria | PL-PEG-SWNT | Photoacoustic therapy | Breast cancer | Transform pulse laser energy into sound energy, bomb the mitochondria into dysfunction and trigger mitochondrial outer membrane permeabilization | Show low toxicity without epidermis injury | [ |
| Extracellular matrix | MWNTs | Photothermal therapy | Epidermoid carcinoma | Significant soften tumors together with volume reduction, induce the destruction of collagen and cell damage | N/A | [ |
| Cancer stem cells | SWNT-Raw and SWNT-COOH | Chemotherapy | Osteosarcoma | Specifically bind to TGFβ1-induced activation of TGFβR1 and suppress its downstream signaling, decrease the OSCs population | Exhibit no obvious toxicity to normal cells | [ |
| Tumor vasculature | DOX/CD-CNT and CUR/CD-CNT | Photothermal therapy + Chemotherapy | Hepatocellular carcinoma | Enhance drug entrapment efficiency and achieve sustained release of both drugs | Cause minimal damage to normal cells | [ |
| Tumor vasculature | iRGD-PEI-MWNT-SS-CD/pAT2 | Chemotherapy | Lung cancer | Promote the cellular uptake and transfection efficiency, inhibit angiogenesis, suppress tumor growth significantly | Not induce obvious tissue damage or inflammatory cell infiltration, not affect blood, hepatic or kidney function in mice | [ |
| PD-1/PD-L1 | Rg3-CNT | Immunotherapy | Triple-negative breast cancer treatment | Inhibit PD-1/PD-L1 axis and the TNBC cell growth | N/A | [ |
| Immune cells | MWNTs-DOX and MWNTs-CpG | Immunotherapy + Chemotherapy + Phototherapy | Melanoma | Inhibit tumor growth, enhance the number of CD4+ and CD8+ T cells, promote TAM shifting, reduce the number of Tregs in TME | Show non-toxicity to the organs (liver, spleen, kidneys, heart and lungs) in mice | [ |
Fig. 3Schematic demonstration of intracellular targeting spots, uptake and cellular fate of CNT-based DDS
Fig. 4Gene therapy mechanisms of siRNA-loaded CNTs and pDNA-loaded CNTs in cancer treatment
Fig. 5Schematic demonstration of the construction and working mechanism of PEG-CNTs-ABT737 nanodrug for anticancer therapy
Fig. 6Schematic graph of CNT-based DDS in TME targeting
Fig. 7Schematic illustration of the working mechanism and therapeutic effects of SWNT-COOH on OSCs targeting
Fig. 8An overview of the contributions of CNTs to cancer diagnosis
Summary of the application of CNTs in cancer diagnosis
| Type of CNTs | Diagnostic methods | Effect | Refs. |
|---|---|---|---|
| SWNTs | Raman Imaging | Strong spots of Raman signals derived from the o-SWNTs-PEG in colon-26 cells can be obtained 5 days after administration | [ |
| SWNTs | Raman Imaging | Possess a strong SERS effect suitable for labeling and fast Raman spectroscopic imaging of biological samples | [ |
| SWNTs | MRI | Exhibit excellent MRI function for tumor diagnosis | [ |
| MWNTs | MRI | Magnify the longitudinal proton relaxation process, possess T1 enhanced MRI effect | [ |
| MWNTs | Ultrasonography | Show high contrast in ultrasonic imaging | [ |
| MWNTs | Ultrasonography | Exhibit the ultrasound signal with strong, long-lived and high-quality properties after sonication treatment | [ |
| SWNTs | PA Imaging | Shows obvious and stable PA signals | [ |
| MWNTs | PA Imaging | Precisely target to the tumor site in vivo, strong PA imaging effect can be obtained | [ |
| MWNTs | Radionuclide Imaging | Enable easy and direct SPECT/CT imaging | [ |
| SWNTs | Radionuclide Imaging | Achieve efficient tumor tissue accumulation for the subsequent radionuclide imaging | [ |
| SWNTs | NIRF imaging | Produces outstanding signal-to-noise performance and exhibits the high specificity towards the in situ ovarian tumor and the implanted tumor nodules | [ |
| SWNTs | NIRF imaging | Obtain high-resolution intravital tumor vessel images through the thick skin in live mice | [ |
| MWNTs | Nanobiosensor | Obtain high biosensing ability, and provide a wide linear range for detecting miR-21 with a very low detection limit in the early diagnosis of pancreatic cancer | [ |
| SWNTs | Nanobiosensor | Exhibit broad detection range, low detection limit, and high specificity to only OPN during prostate cancer detection | [ |
| MWNTs | Nanobiosensor | Achieve the simple detection of CDK1, and report the enzymatic activity of CDK1 for cancer diagnosis | [ |
| MWNTs | Nanobiosensor | Possess high selectivity and sensitivity to HPV-18 for the early, rapid, easy, and accurate diagnosis of cervical cancer | [ |